Polaris Partners logo

Polaris Partners

Crunchbase
Pitchbook
Crunchbase

Deals on record

12

Common Fundraising Type

Equity

Leyden Labs logo
Leyden Labs

Mucosal Protection

ClavystBio logo
Qiming Venture Partners logo
Polaris Partners logo
GV logo
Casdin Capital logo
F-Prime Capital logo
Invus logo
Byers Capital logo

Leyden Labs develops non-vaccine intranasal antibody treatments to protect against respiratory viruses like influenza and coronaviruses.

Equity
$70M
01/09/2025
Article
FIRE1 logo
FIRE1

Connected medical device

Polaris Partners logo
Elevage Medical Technologies logo
Seventure Partners logo
Sands Capital logo
Novo Holdings logo
NEA logo
Medtronic logo
Lightstone Ventures logo

FIRE1 is a connected medical device solutions company focused on developing a heart failure management platform that enables patient self-management and reduces healthcare burdens.

Equity
$120M
01/07/2025
Article
Freckle logo
Freckle

Data enrichment

Polaris Ventures logo
Mintaka VC logo
CoVentures logo
Brenteca Investments logo
Asymmetric Capital Partners logo

Freckle is a data enrichment and research platform designed for non-technical users.

Seed
$1.9M
12/02/2024
Article
TRexBio logo
TRexBio

Biotechnology

Delos Capital logo
Avego BioScience Capital logo
SV Health Investors logo
Pfizer Ventures logo
Polaris Partners logo
Johnson & Johnson logo
Eli Lilly and Company logo
Agent Capital logo

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Series B
$84M
11/13/2024
Article
Sunbird Bio logo
Sunbird Bio

Biotechnology

Polaris Partners logo
S32 logo
Eli Lilly and Company logo
EDBI logo
ClavystBio logo

Sunbird Bio develops a blood-based diagnostic platform for early and accurate detection of neurological disorders like Alzheimer’s and Parkinson’s disease.

Equity
$14M
10/16/2024
Article
Candid Therapeutics logo
Candid Therapeutics

Biotechnology

Venrock Healthcare Capital Partners logo
Vida Ventures logo
TCGX logo
Third Rock Ventures logo
Soleus Capital logo
Samsara BioCapital logo
Redmile Group logo
Polaris Innovation Fund logo

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

Equity
$370M
09/09/2024
Article

Noetik is an AI-native biotech company that leverages spatial omics data and high-throughput CRISPR technology to develop precision oncology therapies.

Series A
$40M
08/29/2024
Article
BeMe Health logo
BeMe Health

Digital behavioral health

Hesperia Capital logo
Polaris Partners logo
Flare Capital logo
Fiore Ventures logo
California Health Care Foundation logo
BCBS of Kansas logo

BeMe Health is a digital behavioral health startup that provides 24/7 accessible mental health interventions and personalized support for teens.

Equity
$12.5M
08/22/2024
Article
Lyndra Therapeutics logo
Lyndra Therapeutics

Clinical-stage biopharmaceutical

Sun Pharmaceutical Industries logo
Sarissa Capital logo
Polaris Partners logo

Lyndra Therapeutics is a clinical-stage biopharmaceutical company developing long-acting oral drug therapies, including a once-weekly oral version of risperidone for psychiatric disorders.

Series E
$101M
12/21/2023
Article

Seismic Therapeutic is a biotechnology firm specializing in the development of immunology drugs using a machine learning-enabled platform to advance its biologics pipeline through clinical trials.

Series B
$121M
12/04/2023
Article
Engine Biosciences logo
Engine Biosciences

Precision Oncology

ClavystBio logo
Polaris Partners logo
SEEDS Capital logo
Invus logo
EDBI logo
Coronet Ventures logo

Engine Biosciences uses machine learning and high-throughput biology to develop precision oncology medicines, and with their recent funding, they plan to advance their biomarker and target discoveries toward the clinic through internal development, collaborations, and partnerships.

Series A
$27M
10/31/2023
Article

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series A
$92M
10/26/2023
Article